GlassScriptPhysician profile
Irina Dawson
NPI 1992190946
$3,949.56
in general payments reported to CMS, 2019-2025
29 companies · $1,271 in 2025
The $1,271 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $621 · 2020: $191 · 2021: $265 · 2022: $688 · 2023: $290 · 2024: $623 · 2025: $1,271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,173 · Education: $11.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,172.88 |
| Education | $11.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $820.47 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $676.60 | 2021-2025 | Fasenra, Airsupra, Tezspire |
| Csl Behring | $384.37 | 2019-2025 | Andembry, Haegarda |
| Regeneron Healthcare Solutions, INC. | $249.39 | 2022-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $241.90 | 2022-2025 | |
| Genentech USA, INC. | $230.45 | 2019-2025 | Xolair |
| Genzyme Corporation | $182.05 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $171.96 | 2020-2025 | Cuvitru, Eohilia |
| Shire North American Group INC | $121.87 | 2019 | |
| Amgen INC. | $120.55 | 2021-2025 | Tezspire |
| Kaleo, INC. | $84.98 | 2020-2022 | |
| Phadia US INC. | $79.30 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $69.32 | 2025 | Neffy |
| Pfizer INC. | $67.31 | 2021-2024 | |
| Optinose US, INC. | $60.06 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $54.60 | 2022 | |
| Incyte Corporation | $47.65 | 2022-2023 | Opzelura |
| Ionis Pharmaceuticals, INC. | $47.13 | 2025 | Dawnzera |
| Leo Pharma INC. | $35.87 | 2023-2024 | Adbry |
| Pharming Healthcare, INC. | $33.73 | 2022-2025 | Ruconest |
| Alk-Abello, INC | $28.37 | 2019-2022 | |
| Octapharma USA, INC. | $24.29 | 2019 | |
| Horizon Therapeutics Plc | $22.21 | 2022 | |
| Blueprint Medicines Corporation | $18.11 | 2025 | Ayvakit |
| Biocryst US Sales Co., LLC | $16.52 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.24 | 2020 | |
| Galderma Laboratories, L.P. | $15.65 | 2025 | Nemluvio |
| Cycle Pharmaceuticals INC | $15.16 | 2025 | Sajazir |
| Hikma Pharmaceuticals USA | $13.45 | 2024 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irina Dawson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.